Results 71 to 80 of about 69,036 (281)

Speech Biomarkers From Smartphone Calls Track Progression in REM Sleep Behavior Disorder and Parkinson's Disease

Annals of Neurology, EarlyView.
Objective This 24‐month longitudinal study involving isolated rapid eye movement sleep behavior disorder (iRBD), early‐stage Parkinson's disease (PD), and matched healthy control subjects aimed to assess whether acoustic speech features from real‐world smartphone calls provide passive progressive biomarkers in synucleinopathies.
Michal Šimek, Tereza Tykalová, Michal Novotný, Vojtěch Illner, Tomáš Kouba, Martin Šubert, Pavel Sovka, Jan Švihlík, Evžen Růžička, Karel Šonka, Petr Dušek, Jan Rusz   +11 more
wiley   +1 more source

Fibroblast Transcriptomics in Molecular Diagnostics of a Comprehensive Dystonia Cohort

Annals of Neurology, EarlyView.
Objective Genomic sequencing leaves >50% of dystonia‐affected individuals without a diagnosis. Where DNA‐oriented approaches remain insufficient, integrating multiomics is essential to advance genome interpretation. Herein, we incorporated RNA sequencing (RNA‐seq) data from 167 patients with dystonia across a range of ages and presentations. Methods We
Alice Saparov, Ivana Dzinovic, Theresa Brunet, Vicente A. Yépez, Florian Hölzlwimmer, Elisabetta Indelicato, Birgit Assmann, Susann Badmann, Diana Ballhausen, Steffen Berweck, Felix Brechtmann, Melanie Brugger, Kevork Derderian, Felix Distelmaier, Philip Harrer, Denisa Harvanova, Petra Havrankova, Ann‐Kathrin Jaroszynski, Miriam Kolnikova, Robert Kopajtich, Anne Koy, Magdalena Krygier, Lukas Kunc, Katarina Kusikova, Oliver Maier, Maria Mazurkiewicz‐Bełdzińska, Christian Mertes, Ava Oberlack, Timo Roser, Alexandra Sitzberger, Ugo Sorrentino, Antonia M. Stehr, Katharina Vill, Matias Wagner, Holger Prokisch, Sylvia Boesch, Jan Necpal, Robert Jech, Juliane Winkelmann, Elisabeth Graf, Julien Gagneur, Matej Skorvanek, Michael Zech   +42 more
wiley   +1 more source

A phase I study to evaluate the effect of high-dose carbidopa on levodopa pharmacokinetics

Frontiers in Pharmacology
Levodopa is the gold standard treatment for Parkinson’s disease. However, a high unmet medical need exists for longer-lasting oral levodopa formulations to achieve sustained motor improvement with reduced risk of the effect wearing off.
Akane Hayashi, Atsushi Hosomi, Shinsaku Kihara, Masato Nishi, Saori Torisawa, Yoshiumi Ouchi, Hidenori Takada, Junichi Enokizono   +7 more
doaj   +1 more source

Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. [PDF]

, 2019
ObjectiveTo understand the safety, putaminal coverage, and enzyme expression of adeno-associated viral vector serotype-2 encoding the complementary DNA for the enzyme, aromatic L-amino acid decarboxylase (VY-AADC01), delivered using novel intraoperative ...
Bankiewicz, Krystof S, Boot, Brendon, Christine, Chadwick W, Kells, Adrian P, Larson, Paul S, Martin, Alastair J, Nutt, John, Ravina, Bernard, Richardson, R Mark, Thompson, Marin E, Van Laar, Amber D   +10 more
core   +1 more source

Nanomaterial‐Mediated Near‐Infrared Photothermal Neuromodulation for Neurologic Disorders

Advanced NanoBiomed Research, EarlyView.
This review summarizes how near‐infrared light activates photothermal nanomaterials to enable noninvasive neuromodulation with high spatiotemporal precision. It elucidates the underlying mechanisms, explores targeted therapeutic applications for neurological disorders, discusses integration with optogenetics and biosensors, and addresses future ...
Ting‐Ting Zeng, Yu‐Ge Wang, Ya‐Bing Zhang, Yuan‐Xin Bai, Si‐Tong Lin, Ting‐Ting Zhu, Yan‐Bo Zhou, Wei‐Tong Pan, Pan‐Miao Liu, Jian‐Jun Yang   +9 more
wiley   +1 more source

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease

Therapeutic Advances in Neurological Disorders, 2018
Motor fluctuations complicate the treatment of patients with Parkinson’s disease receiving levodopa. Extended-release carbidopa–levodopa has a pharmacokinetic profile that provides a more continuous levodopa serum concentration.
Jason Margolesky, Carlos Singer
doaj   +1 more source

Intrastriatal Memantine Infusion Dampens Levodopa-Induced Dyskinesia and Motor Deficits in a Mouse Model of Hemiparkinsonism

Frontiers in Neurology, 2019
Although the administration of dopamine precursor levodopa remains as the mainstay for the treatment of Parkinson's disease, long-term exposure to levodopa often causes a disabling complication, referred to as levodopa-induced dyskinesias. Therefore, the
Masatoshi Ogawa, Masatoshi Ogawa, Yu Zhou, Yu Zhou, Ryosuke Tsuji, Ryosuke Tsuji, Jiro Kasahara, Jiro Kasahara, Satoshi Goto, Satoshi Goto   +9 more
doaj   +1 more source

Orthostatic stability with intravenous levodopa [PDF]

PeerJ, 2015
Intravenous levodopa has been used in a multitude of research studies due to its more predictable pharmacokinetics compared to the oral form, which is used frequently as a treatment for Parkinson’s disease (PD).
Shan H. Siddiqi, Mary L. Creech, Kevin J. Black   +2 more
doaj   +2 more sources

The impact of motor symptoms on self-reported anxiety in Parkinson's disease [PDF]

, 2017
OBJECTIVE: Anxiety is commonly endorsed in Parkinson's disease (PD) and significantly affects quality of life. The Beck Anxiety Inventory (BAI) is often used but contains items that overlap with common PD motor symptoms (e.g., “hands trembling”). Because
Cronin-Golomb, A., Le, A. M., Neargarder, S., Salazar, R. D.   +3 more
core   +1 more source

Bridging the Gap: Integrating Energy Management with Moisture‐Electric Energy Harvesting

Advanced Physics Research, EarlyView.
This review explores energy management strategies that have been successfully applied in other energy harvesting systems, with the aim of adapting such strategies for MEG applications. Through analysis, learning, and adaptation of these existing systems, it is possible to help MEGs achieve more stable electrical output and accelerate their real‐world ...
Zhongliang Zhang, Renbo Zhu, Xiaoming Tao   +2 more
wiley   +1 more source